Physicians and researchers from across the country feature in the Fluminense Oncology Symposium, organized by the IMNE Group
This month, at Campos dos Goytacazes, medicine, science, and technology have taken a higher profile with the 5th Fluminense Symposium on Oncology. On the 19th and 20th, the Instituto Câncer do Norte Fluminense and OncoBeda (IMNE Group) brought together some of the most important Brazilian doctors and researchers. They addressed, among other topics, the importance of precision medicine, the use of technologies such as robotic surgery, as well as innovative treatments and drugs in the fight against cancer.
For IMNE Oncology Group Clinical Director Diogo Neves, the science event at Campos reinforces the institution’s interest in research, technology investment and high-quality cancer treatment.
“We were able to bring a lot into the daily practice of what was discussed in the symposium. Oncology is a discipline that is developing very rapidly. Information needs constant updating. It takes a certain amount of dedication to be able to offer the best treatment and the best options. The people who attended the symposium are at the forefront. Medicine.We have had speakers who have participated in closely related international studies.They are professionals who have given us more nuanced experiences,such as the use of new drugs on the market,Neves summarizes.
According to IMNE’s Clinical Director, André Porto, the Fluminense Oncology Symposium initiative combines the IMNE Group’s and region-wide cancer care practice with global best practices. “We focus this activity on quality and double-edged accuracy. We strive to provide the quality and assistance associated with precision medicine. It is about individualizing treatment with molecular and genetic testing. All this is provided by the IMNE Oncology Group. In practice, this translates to pro-patient care. We have advanced oncology with very valuable results, in the sense of adding quality of life. This patient and his family include the proposed treatment. When we talk about precision medicine, we want long-term results. In other words, patients experience a satisfactory lifespan and minor side effects,” explains Porto.
Since 2015, the Fluminense Oncology Symposium has been part of the list of the most relevant scientific events held in Brazil. IMNE Oncology’s radiation oncologist, Ronaldo Cavalieri, is one of the organizers. “This meeting is essential for our region. We need to participate in educational activities that benefit our patients. Everyone leaves here with the best quality scientific information from top specialists,” he sees.
IMNE Oncology Group’s Thoracic Surgery Coordinator, Ivan Azevedo, moderated discussions on “minimally invasive approach to complex cases”, “quality standards in thoracic oncology surgery” and “technical aspects, design and planning”, with surgeon Ricardo Salgado and speakers Daniel Bonomi, Stefan Soder and Rodrigo. Henriot.
“They highlight early-stage diseases, very complex surgeries and techniques that we don’t yet offer in Campos, but Geral D. Bedi Hospital is already researching. We need less invasive procedures. Robotic surgery is an ongoing investment. IMNE cares about the quality of cancer surgery.” The group of oncology is becoming increasingly multidisciplinary. There is no longer any decision-making alone in oncology. It has already been scientifically proven that the treatment of a patient is less when he undergoes a multidisciplinary team. “Even the cost of treatment is lower,” says Dr. Ivan Azevedo.
Robotic surgery in the spotlight
For Dr. Gustavo Araujo, a member of the Urological Oncology Sector of the IMNE Group, the symposium puts Campos dos Goytacazes in the spotlight on local and national scenarios regarding cancer treatment. Campos is becoming a growing reference in cancer care. We have in the symposium drop surgeons who use the latest technology, specialize in robotic surgery,” he comments.
The director of the Urological Institute of Rio de Janeiro, Jose Milfont, also spoke about robotic surgery. “In my case, robotic surgery stands out as one of the best treatments for kidney cancer. Surgical treatment has developed. This technique is already a reference in many centers in Brazil, and it is likely that it will be implemented quickly in Campos. The patient recovers faster.
Dr. Rodrigo Fruta, of Rede D’Or in Rio de Janeiro, praised the Fluminense Conference, in Campos, and highlighted the importance of technology in oncology: “This event provides the most up-to-date information on the latest cancer treatment in all fields,” outlining
Thoracic surgeon from Santa Casa de Porto Alegre, Stefan Soder, was also at the Fluminense Oncology Symposium. “It is very important to discuss lung cancer and the quality of care. From the point of view of surgery, there are different quality standards. We discuss here how to provide the best outcome for the tumors, that is, the best outcome for patients,” he summarizes.
Dr. Daniel Bonomi is a robotic surgeon at Rede Materdei, in Belo Horizonte. Talk about the impact of technology on cancer treatment today. “With the development of robotic surgery and its benefits, we have deployed this technology, reduced costs, and performed it across the country. He points out that this benefits patients and clinicians who are increasingly working with greater quality and safety of care.
Mastology under analysis
One of the discussion tables during the Fluminense V Oncology Symposium was moderated by Clinical Director Diogo Neves and Breast Specialist from the IMNE Group, Maria Najimi. Among the topics covered with the guest physicians was “Primary Tumor Surgery in Breast Cancer”. “Bi-Rads 3 – Questions and Answers”; and “Her2+ metastatic breast cancer.” An oncologist and oncologist from São Paulo, Vanessa Preti, explained about the treatment of Her2-positive metastatic breast cancer. As she explained about medicine innovative in treating disease:
“Trastuzumab deruxtecan is a very innovative drug, conjugated between antibodies and drugs. This drug has transformed the treatment of metastatic Her2 positive breast cancer, being a paradigm shift in the treatment of this type of tumor. These recent years have been very important for breast tumors. We have gained drugs Excellent with therapeutic benefits not seen in recent decades.These are the results of very encouraging studies that are already transforming the practice of clinical oncologists, PRETTY.
Dr. Erica Endo works at the National Cancer Institute and Grupo Fleury in São Paulo. For the first time in Campos, I discussed the quality of service in mammography. “I was invited to talk about the common doubts about the application of ACR BI-RADS3, which are possibly benign lesions, where control by imaging scans is a safe alternative to biopsy or surgery. The difficult thing is knowing how to properly select these lesions. In the interactive discussion, I made points important about injuries and their application in daily practice, with very recent information in the area,” he said.
The Oncology Symposium also hosted a multidisciplinary journey on palliative care, coordinated by physician from the IMNE Group, Elizabeth Uhl.
“All the opportunities for us to discuss palliative care in a serious and systematic way, we will do that. The patient needs to be understood in the physical context, but also in the social, emotional and spiritual aspects. We can deliver palliative care rigorously, with scientific knowledge. In this seminar, we had people with knowledge and training.” No one does palliative care alone. It is important that all of us clinicians understand that such care is multidimensional. He concludes that palliative care is a multidisciplinary approach aimed at alleviating the suffering, controlling symptoms, and quality of life, from the diagnosis of any life-threatening illness.”